[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-prophylaxis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-prophylaxis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641611","phase-4-comparison-of-propranolol-flunarizine-and-their-combination-in-preventing-migraine-in-adults-in-a-tertiary-care-hospital-in-bangladesh-100641611",false,"NCT07655700","Comparison of Propranolol, Flunarizine and Their Combination in Preventing Migraine in Adults in a Tertiary Care Hospital in Bangladesh","Comparative Efficacy of Propranolol, Flunarizine, and Their Combination in Migraine Prophylaxis: An Open-label Parallel-arm Randomized Controlled Trial","Inclusion Criteria:\n\n1. Participants aged 18 to 55 years.\n2. Diagnosis of episodic migraine, defined according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.\n3. Participants experiencing 4 or more migraine attacks per month.\n4. Willingness to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Comorbidities:\n\n   * Presence of other primary headache disorders, chronic migraine, hemiplegic migraine, basilar migraine or any secondary headache disorder.\n   * Known serious underlying systemic diseases including Cardiac disease (Heart failure, Heart Block, Arrhythmia), Renal dysfunction, Liver dysfunction, Pulmonary disease (Asthma, COPD), Peripheral vascular disease, Extrapyramidal disease (Parkinson disease, Chorea, Dystonia).\n   * Pregnancy or breastfeeding.\n   * Psychiatric illness (Depression, Psychosis, Obsessive compulsive disorder).\n2. Medications:\n\n   * Received migraine prophylactic medication within 60 days prior to screening.\n   * Use of specific contraindicated medications, including beta-blockers or calcium channel blockers, except as part of the study treatments.\n3. Non-compliance:\n\n   * Inability or unwillingness to comply with study protocols, including maintaining a headache diary or attending follow-up visits.\n4. History of Allergies:\n\n   * Known hypersensitivity to propranolol, flunarizine\n5. Substance Use:\n\n   * Current substance abuse","ALL","18 Years","55 Years",{"count":20,"type":21},177,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Migraine is a common and disabling neurological condition that affects quality of life, work productivity, and daily functioning. In Bangladesh, migraine is a major health problem, yet access to effective and affordable preventive treatments remains limited. Preventive (prophylactic) treatment is recommended for people who experience frequent migraine attacks in order to reduce the number, severity, and duration of headaches.\n\nPropranolol and flunarizine are two commonly used and relatively inexpensive medications for migraine prevention. Both drugs have been shown to reduce migraine frequency when used alone. However, some patients do not respond adequately to a single medication. Using a combination of drugs that work through different mechanisms may improve treatment effectiveness without significantly increasing side effects. There is limited local evidence comparing propranolol, flunarizine, and their combination in migraine prevention, particularly in the Bangladeshi population.\n\nThis study is designed to compare the effectiveness and safety of propranolol alone, flunarizine alone, and a combination of propranolol and flunarizine in preventing episodic migraine in adults. The main hypothesis is that at least one of these treatment strategies, particularly combination therapy, may be more effective than the others in reducing migraine burden.\n\nThis is an open-label, parallel-arm, randomized controlled trial conducted at Chittagong Medical College Hospital, Bangladesh. A total of 177 adult patients aged 18 to 55 years who are diagnosed with episodic migraine and experience four or more migraine attacks per month will be enrolled. Participants will be randomly assigned to one of three treatment groups: propranolol, flunarizine, or a combination of both medications. Treatment will be given for 12 weeks, with dose adjustments during the first week and follow-up visits at 6 and 12 weeks.\n\nThe primary outcome of the study is the reduction in the number of monthly migraine days. Secondary outcomes include the proportion of patients achieving at least a 50% reduction in migraine days, changes in headache severity and duration, improvement in migraine-related disability (measured by the Migraine Disability Assessment Score), patient-reported treatment satisfaction, and the frequency of side effects.\n\nThe results of this study are expected to provide important local evidence to guide clinicians in selecting effective and affordable migraine preventive treatments and to clarify whether combination therapy offers additional benefits over single-drug therapy in routine clinical practice.",[27],"Migraine Prophylaxis",[27,29,30,31,32],"Randomized Controlled Trial","Combination Therapy","Propranolol","Flunarizine","NOT_YET_RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2027-04-30",{"name":43,"class":44},"Chittagong Medical College","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100572060","the-real-world-study-of-rimegepant-treatment-in-female-migraine-patients-of-china-100572060","NCT06728345","The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China","The Real-world Study of Rimegepant for the Preventive Treatment in Female Migraine Patients","Inclusion Criteria:\n\n1. Female participants aged ≥ 18 years-old\n2. Primary diagnosis of migraine according to ICHD-3 3.4 or more migraine days during Observation Period and Screening Visit\n\n4.Migraine attacks present for more than 1 year 5.Rimegepant is prescribed for the preventive treatment of migraine by physician 6.Written informed consent must be obtained before participant is enrolled 7.Not concurrently participating in other interventional clinical studies.\n\nExclusion Criteria:\n\n1. Patients diagnosed with secondary headaches.\n2. Women who are pregnant or breastfeeding.\n3. Subjects with severe impairments in language, vision, memory, or cognitive function that affect communication and understanding, or those who are unable to complete questionnaires or follow-ups.\n4. Subjects lacking the equipment to complete questionnaires on a digital platform.\n5. Subjects who are allergic to rimegepant or any of its excipients.\n6. Patients with severe liver damage or end-stage renal disease.\n7. Patients with a medical history indicating the presence of uncontrolled or unstable cardiovascular disease (such as ischemic heart disease, coronary artery spasm, or cerebral ischemia), or those who have had a myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transient ischemic attack within 6 months prior to the screening visit.\n8. Any condition deemed by the investigator that might affect the patient's participation in the study.","FEMALE","65 Years",{"count":56,"type":21},300,"OBSERVATIONAL","The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings :\n\n1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12\n2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12",[60,27],"Migraine","2024-12-06",{"date":63,"type":37},"2024-12-11",{"date":65,"type":21},"2024-12-01",{"date":67,"type":21},"2027-12-31",{"name":69,"class":44},"The First Affiliated Hospital of Soochow University"]